Thanks to the work of NEI scientists and grantees, we’re constantly learning new information about the causes and treatment of vision disorders. Get the latest updates about their work — along with other news about NEI.
Researchers have developed a new gene therapy that could eventually provide an alternative treatment for Fuchs’ endothelial corneal dystrophy, a genetic eye disease affecting roughly one in 2,000 people globally.
A multi-institutional study finds that COVID-19 can be found in post-mortem corneal tissue, highlighting the importance of the donor screening process.
A new study from University of Connecticut details a method of characterizing every cell in the cornea using an approach known as single-cell RNA sequence analysis to answer questions about the cornea’s healing process.
New findings from researchers at Washington University School of Medicine in St. Louis suggest the eye’s cornea can resist infection from the novel coronavirus.
Harvard Medical School surgeons at Massachusetts Eye and Ear have replaced the ocular surface of four patients who each experienced chemical burns to one eye.
The molecular changes that lead to Fuchs’ endothelial corneal dystrophy (FECD) occur decades before the disease causes blurry vision and other noticeable symptoms in patients, new research by UT Southwestern scientists shows.
New research by bioengineer David Schmidtke is helping understand how corneal repair cells called keratocytes sometimes result in scarring and blindness.
Researchers at the University of Illinois at Chicago are the first to identify the presence of a specific type of antibody, called anti-citrullinated protein autoantibodies, or ACPAs, in human tear fluid.
Participants in a phase I/II clinical trial of a new enzyme-based treatment for severe dry eye disease experienced reduced signs of disease and discomfort, according to a paper in Translational Vision Science and Technology.
Omega-3 fatty acid supplements taken orally proved no better than placebo at relieving symptoms or signs of dry eye, according to the findings of a well-controlled trial funded by the National Eye Institute (NEI), part of the National Institutes of Health
